Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Alan Meds vs Citizen Meds

An in-depth comparison of two leading GLP-1 Providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.7

Alan Meds

Best for budget-conscious shoppers
★★★3.9

Starting at $99/mo

CompoundedSemaglutideTirzepatideOral Format
Visit Alan Meds
7.0

Citizen Meds

Best for pending full verification
★★★3.5
Semaglutide
Visit Citizen Meds

Side-by-Side Comparison

FeatureAlan MedsCitizen Meds
Overall Score7.7/107.0/10
Starting Price$99/mo
Editorial Rating3.9 ★ /53.5 ★ /5
Features5 features1 features
States Available460
Compounded✓ Yes
Brand Name
FSA/HSA Accepted
FDA WarningsNoneNone

Pros & Cons

Alan Meds

Pros

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access
  • Multiple administration formats

Cons

  • Limited public information on program details

Citizen Meds

Pros

  • Semaglutide confirmed from product listings
  • New patient discount available (NEWPATIENT10)

Cons

  • Pricing not publicly visible (JavaScript-rendered WooCommerce store)
  • No visible LegitScript or PCAB accreditation
  • State availability not disclosed
  • About page returns 404
  • Limited transparency — needs Chrome MCP verification for full product/pricing data

Our Verdict

Winner: Alan MedsScore: 7.7/10

Alan Meds edges out Citizen Meds with a higher overall score of 7.7/10 and is particularly strong for budget-conscious shoppers. Citizen Meds remains a solid alternative, especially if you're looking for pending full verification.

Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.